A baby born Nov. 22 in Leicester, England, has a chance to beat the odds and survive after a rare congenital condition caused her to be delivered a month early with her heart beating outside her chest cavity.

San Diego, Calif. — Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate, RT-100 AC6 gene transfer (Ad5.hAC6), for the treatment of heart failure with reduced ejection fraction (HFrEF).

Spinal cord injuries (SCIs) directly affect the heart, but the extent of any damage done is reliant on the severity of an SCI, new research out of the University of British Columbia, Canada, states.

PQ Bypass has received an investigational device exemption from the FDA to initiate the first pivotal clinical trial of percutaneous femoropopliteal bypass for patients with peripheral artery disease (PAD), according to a press release.

Children born to diabetic mothers are up to five times more likely to be diagnosed with congenital heart disease, University of California, Los Angeles (UCLA) researchers reported this week in a novel study linking diabetic pregnancies and fetal heart conditions.

Children with diabetes are seven times more likely to experience sudden cardiac death than their non-diabetic peers, according to research reported by the American Heart Association this week.

Nanette Wenger, MD, became the chief of cardiology at Grady Memorial Hospital in Atlanta in 1958, when black patients and nurses were systematically addressed differently than their white counterparts and cardiovascular disease was assumed to be a “man’s disease.”

The two lead investigators of ORBITA have published a comprehensive response to criticisms of their provocative trial.